Wikipedia
WASHINGTON — There’s about to be a new acronym in town.
The Food and Drug Administration is in the final stages of cementing sweeping changes to the Office of Regulatory Affairs, which oversees inspections and compliance for all its regulated products, according to three people familiar with the planning.
advertisement
That overhaul includes a new name: Meet the Office of Inspections and Investigations.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
ASCO Daily Recap: Safety data from Novartis, survival from Pfizer
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
